Crinetics Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Checking your notes…
(in thousands)
| Common StockShares · Common Stock and Paid-InCapital · AccumulatedOtherComprehensiveIncome (loss) · AccumulatedDeficit · Stock Held inTrust · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance at April 1, 2026 | 105,314 | $2,828,204 | $(1,254) | $(1,545,272) | $(1,032) | $1,280,646 | |||||
| Exercise of stock options | 233 | 4,697 | — | — | — | 4,697 | |||||
| Stock issued under ESPP | 159 | 4,281 | — | — | — | 4,281 | |||||
| Issuance of common stock upon vesting of RSUs | 102 | — | — | — | — | — | |||||
| Stock-based compensation | — | 24,947 | — | — | — | 24,947 | |||||
| Stock held in trust under deferred compensation plan | — | 231 | — | — | (231) | — | |||||
| Other comprehensive loss | — | — | (1,754) | — | — | (1,754) | |||||
| Net loss | — | — | — | (120,855) | — | (120,855) | |||||
| Balance at June 30, 2026 | 105,808 | $2,862,360 | $(3,008) | $(1,666,127) | $(1,263) | $1,191,962 | |||||
| Balance at January 1, 2026 | 95,575 | $2,407,757 | $1,865 | $(1,417,427) | $(112) | $992,083 | |||||
| Exercise of stock options | 629 | 14,639 | — | — | — | 14,639 | |||||
| Issuance of common stock, net of transaction costs | 8,763 | 379,771 | — | — | — | 379,771 | |||||
| Stock issued under ESPP | 159 | 4,281 | — | — | — | 4,281 | |||||
| Issuance of common stock upon vesting of RSUs | 682 | — | — | — | — | — | |||||
| Stock-based compensation | — | 54,761 | — | — | — | 54,761 | |||||
| Stock held in trust under deferred compensation plan | — | 1,151 | — | — | (1,151) | — | |||||
| Other comprehensive loss | — | — | (4,873) | — | — | (4,873) | |||||
| Net loss | — | — | — | (248,700) | — | (248,700) | |||||
| Balance at June 30, 2026 | 105,808 | $2,862,360 | $(3,008) | $(1,666,127) | $(1,263) | $1,191,962 | |||||
| Balance on April 1, 2025 | 93,525 | $2,300,882 | $2,002 | $(1,048,884) | $— | $1,254,000 | |||||
| Exercise of stock options | 463 | 4,529 | — | — | — | 4,529 | |||||
| Stock issued under ESPP | 115 | 2,880 | — | — | — | 2,880 | |||||
| Issuance of common stock upon vesting of RSUs | 23 | — | — | — | — | — | |||||
| Stock-based compensation | — | 26,124 | — | — | — | 26,124 | |||||
| Stock held in trust under deferred compensation plan | 112 | — | — | (112) | — | ||||||
| Other | 11 | — | — | — | 11 | ||||||
| Other comprehensive income | — | — | (381) | — | — | (381) | |||||
| Net loss | — | — | — | (115,637) | — | (115,637) | |||||
| Balance at June 30, 2025 | 94,126 | $2,334,538 | $1,621 | $(1,164,521) | $(112) | $1,171,526 | |||||
| Balance on January 1, 2025 | 92,926 | $2,275,952 | $963 | $(952,110) | $— | $1,324,805 | |||||
| Exercise of stock options | 678 | 8,981 | — | — | — | 8,981 | |||||
| Stock issued under ESPP | 115 | 2,880 | — | — | — | 2,880 | |||||
| Issuance of common stock upon vesting of RSUs | 407 | — | — | — | — | — | |||||
| Stock-based compensation | — | 46,602 | — | — | — | 46,602 | |||||
| Stock held in trust under deferred compensation plan | — | 112 | — | — | (112) | — | |||||
| Other | — | 11 | — | — | — | 11 | |||||
| Other comprehensive income | — | — | 658 | — | — | 658 | |||||
| Net loss | — | — | — | (212,411) | — | (212,411) | |||||
| Balance at June 30, 2025 | 94,126 | $2,334,538 | $1,621 | $(1,164,521) | $(112) | $1,171,526 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.